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 3 
Abstract 4 
 5 
Activation of thyroxine by outer ring deiodination is the crucial first step of thyroid 6 
hormone action. Substrate-induced ubiquitination of type 2 deiodinase (D2) is the most rapid 7 
and sensitive mechanism known to regulate thyroid hormone activation. While the molecular 8 
machinery responsible for D2 ubiquitination has been extensively studied, the combination of 9 
molecular features sufficient and required to allow D2 ubiquitination remained to be 10 
determined. To address this question we constructed chimeric deiodinases by introducing 11 
different combinations of D2-specific elements into type 1 deiodinase (D1), another member of 12 
the deiodinase enzyme family, which however does not undergo ubiquitination in its native 13 
form. Studies on the chimeric proteins expressed transiently in HEK-293T cells revealed that 14 
combined insertion of the D2-specific instability loop and the K237/K244 D2 ubiquitin-carrier 15 
lysines into the corresponding positions of D1 could-not ubiquitinate D1 unless the chimera was 16 
directed to the endoplasmic reticulum (ER). Fluorescence resonance energy transfer 17 
measurements demonstrated that the C-terminal globular domain of the ER-directed chimera 18 
was able to interact with the E3 ligase subunit WSB1. However, this interaction did not occur 19 
between the chimera and the TEB4 E3 ligase although a native D2 could readily interact with the 20 
N-terminus of TEB4. In conclusion, insertion of the instability loop and ubiquitin-carrier lysines 21 
in combination with direction to the ER are sufficient and required to govern WSB1-mediated 22 
ubiquitination of an activating deiodinase enzyme.  23 
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 24 
 25 
Introduction 26 
 27 
Thyroid hormone activation, the first step of thyroid hormone action is catalyzed by 28 
activating deiodinases, type 1 and type 2 deiodinases (D1 and D2, respectively) via outer ring 29 
deiodination (Gereben, et al. 2008). In a physiological setting, D2 is the major activating 30 
deiodinase (Maia, et al. 2005; Schneider, et al. 2006) and its activity is subjected to complex 31 
controls which also involves ubiquitination of the D2 protein (Gereben, et al. 2000).  32 
Selective proteolysis is driven by the ubiquitin-proteasome system (UPS) and represents  33 
a crucial regulatory mechanism of cell function (Hershko and Ciechanover 1998). Targeting 34 
proteins into the proteasome for degradation is one of the most heavily studied phenomenon 35 
among the diverse set of ubiquitination-controlled cellular functions. Ubiquitination is a three-36 
step process involving ubiquitin activation by the E1 enzyme, conjugation of ubiquitin to E2 37 
followed by specific protein targeting by the E3 ubiquitin ligase complex responsible for 38 
substrate-recognition and specificity (Hershko and Ciechanover 1998). Proteins carrying 39 
degradative ubiquitin signal (e.g. lysine 48-linked polyubiquitin chain) are transferred into the 40 
proteasome to be cleaved to short oligopeptides or amino acids.  41 
D2 is intrinsically unstable and is degraded in the 26S proteasome (Steinsapir, et al. 42 
1998). D2 was identified as the first endoplasmic reticulum resident enzyme undergoing 43 
substrate-induced ubiquitination (Gereben et al. 2000). The ubiquitination of the D2 protein 44 
also involves a degradation-independent mechanism via ubiquitination induced conformational 45 
changes of D2-homodimers that results in quick decline of D2 activity (Sagar, et al. 2007). As a 46 
consequence, ubiquitination is currently considered the most rapid and efficient way to regulate 47 
D2-mediated T3 generation (Bianco and Larsen 2005).  48 
Specific molecular elements were shown to be important for D2 ubiquitination, e.g. an 49 
instability loop between aa. 92-97 and the K237/K244 lysines in the human D2 protein (Dentice, 50 
et al. 2005; Sagar et al. 2007; Zeold, et al. 2006b). Presently, two E3 ligases are known that 51 
contribute to D2 degradation. First the SOCS-box-containing WD-40 protein (WSB1), a sonic 52 
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hedgehog-induced protein was recognized as a D2-inteacting substrate-recognition subunit of 53 
an E3 ligase catalytic core complex (ECSWSB1) that consists of Elongin BC-Cullin5-Rbx1 subunits 54 
(Dentice et al. 2005). Next TEB4, the mammalian orthologue of yeast Doa10 was identified as a 55 
functional E3 ligase for the ubiquitination of D2 (Zavacki, et al. 2009) but molecular details of 56 
the TEB4-D2 interaction remains to be determined.  57 
In contrast to D2, D1 is a long-lived plasma membrane located activating deiodinase that is not 58 
subjected to ubiquitination (Baqui, et al. 2000; Gereben et al. 2000). 59 
Despite accumulating data, the minimal requirements of ubiquitination-mediated 60 
deiodinase regulation have not yet been defined. We aimed to determine the combination of 61 
molecular features required and sufficient to allow an activating deiodinase to be targeted by E3 62 
ubiquitin ligases, a pre-requisite for proteins processed along the ubiquitin-proteasome 63 
pathway. We inserted D2-specific molecular elements into D1 to generate chimeric proteins 64 
that allow assessing the power of specific D2-ubiquitinating elements in the context of a 65 
natively non-ubiquitinated deiodinase protein.  66 
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 67 
 68 
Materials and Methods 69 
 70 
Generation of DNA constructs 71 
FLAG-tagged chimeric deiodinases were constructed using standard recombinant DNA 72 
techniques. Site-directed mutagenesis was performed with Vent polymerase PCR on templates 73 
containing  the human D2 or rat D1 coding region with a cysteine-mutant active-center followed 74 
by cloning into a D10 expression vector (Gossen and Bujard 1992). For FRET experiments the 75 
generated fragments were subcloned into pEYFP-N1 (Clontech, Mountain View USA) resulting 76 
EYFP-fusion to the C-terminus of chimeras.  77 
The human TEB4 coding region was amplified with Vent polymerase on a pcDNA3.1-GFP-78 
TEB4 template  (kind gift of Dr. M. Hochstrasser, Yale University). The product was  subcloned 79 
into pEYFP-N1, pEYFP-C1 and pECFP-C1 fusion vectors (Clontech) that resulted in TEB4-Y (in 80 
pEYFP-N1), Y-TEB4 (in pEYFP-C1) and C-TEB4 (in pECFP-C1). C or Y stands for ECFP or EYFP, 81 
respectively. Construct nomenclature also provides information on the position of the 82 
fluorescent protein in the translated fusion protein (e.g. TEB4-Y indicates that EYFP was fused to 83 
the C-terminus of TEB4 protein, while the C-TEB4 construct containes ECFP at the N-terminus of 84 
TEB4). All constructs were confirmed by sequencing. The D2-Y, D2-C and C-D2 constructs (Vivek 85 
Sagar, et al. 2007) and the  WSB1-C and Sec62-D1 constructs were  described earlier (Vivek 86 
Sagar et al. 2007; Zeold et al. 2006b).  87 
 88 
Cell culture and transfection 89 
HEK-293T (Zeold, et al. 2006a) cells were grown in DMEM (Gibco, New York USA) 90 
supplemented with 10% Fetal Bovine Serum (Gibco, New York USA) and 1% penicillin-91 
streptomycin solution (Sigma, St. Louis, USA). One day before transfection cells were plated into 92 
35 mm-dish at 2×105 cells/hole concentration. Transfections were performed using 93 
Lipofectamine 2000 reagent (Invitrogen, New York USA) following the manufacturers 94 
instruction. Secreted alkaline phosphatase (SEAP) was used as transfection internal control. 48-95 
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hours after transfection cells were harvested and processed for Western blot or deiodinase 96 
activity measurement.  97 
 98 
Reagents and treatments 99 
Tetracycline (Sigma, New York USA) treatment (6- and 12-hours, 1 mg l-1 final 100 
concentration) was performed on the second day after transfection (Gossen and Bujard 1992). 101 
MG132 (Calbiochem, Darmstadt Germany), a protease inhibitor for proteasome activity was 102 
dissolved in DMSO and cells were treated 4 hours using 2 µmol l–1 final concentration versus 103 
vehicle. Hormone-free medium for T4-treatment was prepared with charcoal-stripped FBS. In 104 
brief, 100 mg charcoal (Sigma, New York USA) and 50 mg dextran (Sigma, New York USA) were 105 
preincubated overnight in 0.01 mol l–1 Tris buffer (pH=7.6). After centrifugation 40 ml FBS was 106 
added and incubated for 1 hour. The suspension was recentrifugated and supernatant was 107 
added to DMEM in 1:10 followed by membrane-filtration. 1 mmol l–1 T4 (Sigma, New York USA) 108 
stock solution was kept in NaOH. 109 
 110 
SEAP assay 111 
Media was removed from cells before treatment and processed for SEAP measurement 112 
using NovaBright™ Chemiluminescent SEAP Reporter Gene Assays (Invitrogen, New York USA) 113 
followed by measurement with Luminoscan Ascent (Thermo, Waltham USA) according to the  114 
manufacturer’s instructions. 115 
 116 
Western blot 117 
Western blots were performed as described (Gereben et al. 2000). For the detection of 118 
high molecular weight ubiquitinated bands samples were run in 4-20% gradient gels (Bio-Rad, 119 
Hercules USA). The blots were incubated with M2 anti-FLAG monoclonal antibody (Sigma, New 120 
York USA) using 1:3000 dilution.  121 
 122 
Deiodinase activity assay 123 
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HEK-293T cells were processed for in vitro deiodinase assay to measure the activity of D1 124 
containing a cysteine-mutant active center according to the American Thyroid Association Guide 125 
to investigating thyroid hormone economy and action in rodent and cell models (Bianco, et al. 126 
2014). Basic assay procedure was as previously described (Curcio-Morelli, et al. 2003). In the 127 
present study 125I-T4 and 1 µmol l–1 T4 substrate was used for 3 hours. 128 
 129 
 Fluorescence resonance energy transfer (FRET) and confocal microscopy 130 
Transfection was carried out as described above but the cells were plated into 35-mm 131 
glass-bottom dishes (MatTek Co, Ashland USA). FRET was performed according to our current 132 
protocol (Arrojo, et al. 2013). FRET measurement was performed on the second day after 133 
transfection using acceptor-photobleaching on a Nikon A1R laser scanning confocal system in 134 
spectral detector mode equipped with Tokai Hit stage top incubator and Supertech temperature 135 
controller. Following parameters were applied in FRET experiments: 457 nm argon-laser for 136 
ECFP excitation and 464-500 nm range for detection; 514 nm argon lasers for EYFP excitation 137 
and 516-540 nm range for detection. Cells at least 80% bleach efficiency (decrease in EYFP 138 
intensity) were involved into analysis. At least 20 cells were measured per groups.  139 
Calculation of FRET efficiency was based on the increase of the CFP donor signal after 140 
photobleaching the YFP acceptor using the following equation:  141 
FRET=(CFP(postbleach)-CFP(prebleach))/CFP(postbleach). 142 
 Data normalization was performed by expressing FRET efficiency of specific FRET pairs as a 143 
percentage of that of the ECFP-EYFP (C-Y) tandem construct (Cicchetti, et al. 2004). CFP and YFP 144 
(C and Y) monomers were used to determine background. 145 
 146 
Statistical analysis 147 
Deiodinase activities of MG132 treated samples were analyzed by t-test. FRET results 148 
were analyzed by t-test or one-way ANOVA followed by the Tukey’s post-hoc test.  149 
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 150 
 151 
Results 152 
 153 
Specific D2 elements with known effect on D2 ubiquitination were introduced into rat D1 154 
in homologue positions. The K237/K244 ubiquitin binding lysines of D2 are phylogenetically 155 
conserved but these residues are absent in D1 proteins (Fig.1A). The K237 and K244 lysine 156 
residues of D2 were inserted into rat D1 by generating R223K and P230K D1 mutants, 157 
respectively. The instability loop of D2 (aa. 92-97 of human D2) was inserted between aa. 102-158 
103 of D1 (Fig.1A). Direction of the chimera to stable retention in the endoplasmic reticulum 159 
was achieved by deleting its N-terminal 33 amino acids to remove the transmembrane-domain 160 
and the resulting fragment was fused to the C-terminus of human Sec62, an ER resident protein 161 
using our previously described approach (Zeold et al. 2006b). The constructs are depicted in 162 
Fig.1B. 163 
The half-life of chimeras was tested in HEK-293T cells using the Tet-off expression 164 
system that allows transcriptional suppression of the transfected constructs (Fig.2A) (Gossen 165 
and Bujard 1992). Insertion of the ubiquitin-carrier lysines into D1 (D1-K and D1-2K) did not 166 
result in detectable changes in protein half-life and high-molecular weight ubiquitinated bands 167 
could not be observed on Western-blot (Fig.2B). Insertion of the D2-specific 6 aa.-loop into D1-K 168 
and D1-2K (D1-K-loop and D1-2K-loop) remarkably destabilized the chimera but ubiquitinated 169 
forms did not appear. Importantly, direction of the D1-2K-loop chimera into the ER via fusion to 170 
Sec62 (Sec62-D1-2K-loop) resulted both in destabilization and generation of high molecular 171 
weight ubiquitinated forms (Fig.2B). 172 
Proteasomal uptake of the chimeric proteins was also studied by treating the cultures 173 
with 2 µmol l-1 MG132 for 4 hours followed by the measurement of deiodinase activity. While 174 
activity of the D2 control was readily increased, the D1-K; D1-2K; D1-K-loop and D1-2K-loop 175 
chimeras were not sensitive to MG132 similarly to native D1 indicating that these proteins are 176 
not processed by the proteasome (Fig.2C).  177 
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To test whether the generated chimeric proteins can bind the WSB1 E3 ligase subunit or 178 
the TEB4 E3 ligase, FRET was performed (Fig.3A). While the D2-binding domain of WSB1 has 179 
already been resolved (Vivek Sagar et al. 2007), localization of the substrate recognition surface 180 
of TEB4 has not been described yet. Therefore first we aimed to identify the D2-binding domain 181 
of TEB4. FRET-pairs were constructed fusing EYFP either to N- or C-terminus of TEB4 and tested 182 
in the presence of the ECFP-tagged D2 protein. Since membrane topology and localization of the 183 
TEB4 C-terminal portion is controversial (Hassink, et al. 2005; Kreft, et al. 2006) we tested both 184 
possibilities, i.e. if the C-terminus would be located either the ER-lumen or in the cytosol. 185 
Therefore we measured the interaction of the C-terminus of TEB4 (TEB4-Y) with both the C- and 186 
N-terminus of D2 (D2-C and C-D2) which are localized in the cytosol and ER-lumen, respectively 187 
(Fig.3B,E). Energy transfer could be detected between the N-terminus of TEB4 and the C-188 
terminus of D2 (Y-TEB4 vs. D2-C) (20.04 ± 2.88 %). The strength of the interaction reached ~37 % 189 
of that of the D2-D2 homodimers (D2-C vs. D2-Y) (53.71 ± 1.45 %) (Fig.3C). In contrast, no 190 
energy transfer occurred when the C-terminus of TEB4 was tested either in the presence of the 191 
cytosolic C-terminus (TEB4-Y vs. D2-C) or the ER-lumen localized N-terminus (TEB4-Y vs. C-D2) of 192 
D2 (0.73 ± 1.78 %) (Fig.3C). T4, the substrate known to accelerate D2 ubiquitination increased 193 
the strength of the interaction between the N-terminus of TEB4 and C-terminus of D2 (Y-TEB4 194 
vs. D2-C) by ~40% after 4 h incubation with 10 µM T4 in hormone-free media. However, no 195 
significant change occurred when the C-terminus of TEB4 (TEB4-Y) was tested although the FRET 196 
signal of the D2-D2 homodimer control decreased, as expected (Fig.3D).  197 
We then moved to test the binding of the chimeras to the WSB1 E3 ligase subunit and to 198 
the TEB4 E3 ligase. The chimeras were tagged by EYFP on the C-terminus and energy transfer 199 
was measured in the presence of WSB1 (tagged on the C-terminus with ECFP, WSB1-C) or TEB4 200 
(ECFP on its N-terminus, C-TEB4) following the scheme depicted on Fig.4A. Inserting the 201 
ubiquitin-carrier lysine residues of D2 into D1 by R223K and P230K mutations in the 202 
combination with the 6 aa.-loop (D1-2K-loop-Y) did not result in detectable interaction between 203 
the chimeras and WSB1-C or C-TEB4 and performed similarly to native, or ER-inserted D1 204 
(Sec62-D1-Y) (Fig.4B,C). Interestingly the ER-localized lysines- and 6 aa-loop-containing mutant 205 
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(Sec62-D1-2K-loop-Y) showed measurable FRET signal in pair with WSB1-C (53.14 ± 14.63 %) but 206 
not with C-TEB4 (Fig.4B,D).  207 
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 208 
 209 
Discussion 210 
 211 
Thyroid hormone metabolism catalyzed by selenodeiodinase enzymes allows the 212 
accurate and flexible regulation of tissue-specific thyroid hormone levels (Gereben et al. 2008). 213 
Although both D1 and D2 are capable to generate T3 from thyroxin, under physiological 214 
conditions D2 is the major T3 producer due to its high substrate affinity (Maia et al. 2005). D2 is 215 
subjected to tight and multilevel control (Gereben et al. 2008) that includes substrate-mediated 216 
ubiquitination, a process representing the fastest and most sensitive regulation of thyroid 217 
hormone activation. The efficiency of this process is explained by the complex nature of D2 218 
ubiquitination, that occurs not only via the degradation of the D2 protein, but also involves D2 219 
inactivation in degradation-independent manner due to ubiquitination-induced conformational 220 
changes of the globular domain of the D2  homodimers allowing fast and reversible control of 221 
D2 activity (Sagar et al. 2007). This is especially useful for the cell taking into account both the 222 
energy-consuming multistep process required to incorporate the specific amino acid 223 
selenocysteine into the D2 protein and the need for rapid regulation of D2-mediated T3 224 
generation. In contrast, the D1 protein is not processed along this pathway and represents 225 
stability (Gereben et al. 2000). Subcellular localization of the two enzymes is also different since 226 
D2 is subjected to stable retention in the endoplasmic reticulum while D1 is located in the 227 
plasma membrane (Baqui et al. 2000; Zeold et al. 2006a). 228 
Previous studies identified molecular elements involved in the maintenance of metabolic 229 
instability of the D2 molecule (Dentice et al. 2005; Zeold et al. 2006a). However, the 230 
combination of elements required and sufficient for D2 ubiquitination has not been resolved. In 231 
the present study we used a reversed strategy by incorporating D2-specific elements into the 232 
long-lived deiodinase D1 in order to test the power of specific molecular combinations to 233 
destabilize an otherwise non-ubiquitinated protein. 234 
Insertion of the ubiquitin-binding K237/K244 lysines into homologous positions of D1 235 
(D1-K and D1-2K) were not sufficient to destabilize or ubiquitinate the chimera. Interestingly, 236 
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insertion of the lysines in combination with the D2 instability loop (D1-loop-K and D1-loop-2K) 237 
decreased stability without the appearance of detectable amount of ubiquitinated forms and 238 
remained insensitive to MG132 proving that were not subjected to proteasomal uptake. This 239 
observation raised the possibility that the inherent instability of D2 is not exclusively dependent 240 
on the ubiquitin-proteasome system but might be also affected by other, proteasome-241 
independent mechanisms, as shown for iron regulatory protein 2 and IKBA (Chang, et al. 2011; 242 
Shumway and Miyamoto 2004). However, Sec62-mediated direction of the loop- and lysines- 243 
containing D1 into the ER resulted intense ubiquitination of the chimera indicating that this 244 
combination is sufficient to drive the chimera to the ubiquitin-proteasome pathway. The Sec62-245 
fused deiodinases are inactive due to the lacking transmembrane domain thus their activity 246 
cannot be tested (Zeold et al. 2006a). 247 
Since ubiquitin-ligase binding is crucial for the substrate-specificity of ubiquitination we 248 
studied whether the chimeric proteins could be recognized by the D2-specific E3 ligases WSB1 249 
and TEB4 in live HEK-293T cells. WSB1 is a WD40 repeat and SOCS-box containing protein 250 
(Hilton, et al. 1998). It was demonstrated that WSB1 works as a substrate-recognizing subunit of 251 
a ECSWSB1 E3 ligase complex and mediates substrate induced ubiquitination of D2 (Dentice et al. 252 
2005) binding the C-terminus of D2 via its SOCS-box domain (Sagar et al. 2007). However the 253 
recognition of D2 by TEB4 is less understood. Therefore first we had to identify the D2 254 
interacting domain of TEB4 and showed that its N-terminus is responsible for this action. 255 
Importantly, this region contains the catalytically active RING domain that represents a common 256 
structural unit in an E3 ligase subclass (Deshaies and Joazeiro 2009). Our data demonstrate that 257 
the TEB4 protein integrates the ability of recognition and ubiquitination of D2 and its interaction 258 
with D2 is increased upon T4 exposure that results in substrate-mediated down-regulation of D2 259 
activity. 260 
Having identified the basic topology of the D2-TEB4 interaction we used this information 261 
to perform FRET studies on the interaction between the chimeras and TEB4 and also WSB1. We 262 
obtained evidence that the ubiquitination of D2 lysine- and loop-containing ER-localized 263 
chimera (Sec62-D1-2K-loop) binds WSB1. This demonstrates that the ubiquitination of the 264 
Sec62-D1-2K-loop protein carried out by an E3 ligase driven specific process rather than an 265 
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ERAD-driven clearance mechanism of the exogenous protein. Lack of WSB1 binding of the D1-266 
2K-loop chimera is in accordance with the lack of ubiquitinated forms observed when studying 267 
this chimera by Western blot. Therefore we conclude that insertion of the instability loop and 268 
ubiquitin-carrier lysines into an ER located activating deiodinase are sufficient and required to 269 
govern WSB1 mediated ubiquitination. We could not detect interaction between TEB4 and the 270 
Sec62 fused chimera, although the fusion allowed directing the chimera into the ER-linked 271 
location of native D2, and the C -terminus D2 was able to interact with the N-terminus of Teb4 272 
(Fig 3C). These findings indicate that the lack of interaction between the chimera and Teb4 273 
cannot be explained by topology and Teb4 binding would require still unidentified molecular 274 
elements in the deiodinase protein. 275 
It has been shown that D2 undergoes classical K48-linked ubiquitination targeting the 276 
protein for proteasomal degradation (Arrojo et al. 2013). While data have been accumulating on 277 
the biological significance of unconventional polyubiquitin-chains not composed by K48-linked 278 
ubiquitin (Kulathu and Komander 2012), presently no data are available on such alternatively 279 
linked ubiquitin on the D2 protein. Consequently, it is also unknown whether D2-specific E3 280 
ligases would be differently involved in the generation of alternatively-linked ubiquitin chains, 281 
e.g. via the formation of non-proteasomal signals. These signals could be relevant for D2, since 282 
beyond proteasomal degradation D2 ubiquitination also drives proteasome independent 283 
conformational changes of the D2 homodimers, resulting in transient loss of D2 activity (Sagar 284 
et al. 2007). It has been also demonstrated that Doa10 (yeast orthologue of mammalian TEB4), 285 
in combination with the Ubc6 (yeast orthologue of mammalian UBE2J) ubiquitin conjugating E2 286 
enzyme can be potentially involved in the K11-linked polyubiquitin-chain synthesis (Xu, et al. 287 
2009). Since UBE2J was also shown to be involved in the ubiquitination of D2 (Botero, et al. 288 
2002; Kim, et al. 2003) these data raise the possibility that TEB4 could potentially facilitate K11-289 
linked polyubiquitin-chain formation on D2. 290 
In conclusion, the obtained data identified a combined set of molecular elements and 291 
intracellular localization necessary for WSB1 mediated regulation of thyroid hormone activation 292 
and demonstrated distinct requirements for WSB1 and TEB4-mediated ubiquitination of D2. In 293 
vivo, the complex regulation of deiodination via WSB1 and TEB4 could play a role in D2 294 
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expressing tanycytes of the mediobasal hypothalamus known to coexpress WSB1, TEB4 and 295 
deubiquitinase enzymes (Fekete, et al. 2007; Zavacki et al. 2009).  296 
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Figure legends 403 
 404 
Figure 1. 405 
(A) Alignment of amino acid sequences of D1 and D2 portions in different species. Amino acid 406 
positions indicated using the positons of amino acids in human D2, the first six amino acids of 407 
the D2 specific instability loop and the conserved lysine residues were boxed. Arrows indicate 408 
the position of ubiquitin-carrier lysines of D2. (B) Schematic depiction of the applied D1-D2 409 
recombinant chimeric proteins tagged with a FLAG epitope on the N-terminus. 410 
 411 
 412 
Figure 2. Stability and ubiquitination of chimeric deiodinase proteins.  413 
(A) Experimental design. (B) Assessment of protein stability using of 1 mg l-1 tetracycline 414 
treatment for 12h in HEK-293T cells. FLAG-tag was detected by Western-blot. Open arrows 415 
point to high molecular mass ubiquitinated deiodinase forms. The asterisk labeled inset 416 
demonstrates short exposure of Sec62-D1-2K-loop +/- tetracycline (left and right, respectively) 417 
run in 10 % SDS gel. (C) D1 activity of chimeras expressed in HEK-293T cells treated with 2 µmol 418 
l-1 MG132 for 4-hours. D2 was used as a positive control of MG132 treatment. Activity was 419 
expressed in percentage of the vehicle threated corresponding control (MG132/DMSO) 420 
normalized by SEAP (mean ± SEM; n=3) **: p<0.01 by t-test.  421 
 422 
 423 
Figure 3. Topology and substrate-dependence of the D2-TEB4 interaction assessed with FRET  424 
(A) Experimental design. (B) Schematic depiction of FRET-pairs. Due to the controversial 425 
topology of the C-terminus of TEB4 both cytosolic and ER lumen located positions were 426 
depicted (C) FRET-assisted detection of the topology of TEB4-D2 interaction. Data are expressed 427 
as a percentage of that of the fused ECFP-EYFP (C-Y) tandem positive control while 428 
cotransfected monomeric ECFP (C) and EYFP (Y) were applied to detect non-specific background 429 
(mean ± SEM; n≥15 per group) ***: p<0.001; **: p<0.01 by one-way ANOVA vs. monomer 430 
followed by Tukey’s post-hoc test). (D) Effect of 1 µmol l-1 T4 on the D2-TEB4 interaction. T4 431 
19 
 
sensitive D2 homodimers were used as positive controls (mean ± SEM; n≥15 per group) ***: 432 
p<0.001; **: p<0.01 by two-tailed t-test. (E) Photomicrography of individual HEK-293T cells 433 
demonstrating acceptor photobleaching FRET to detect the interaction between TEB4 and D2. 434 
Left-top: prebleach (pre) acceptor; right-top: postbleach (post) acceptor; left-bottom: 435 
prebleached donor; right-bottom: postbleached donor. The order of the fluorescent protein (C 436 
or Y) and the tagged protein in the name of the constructs reflects their position in the fusion 437 
protein. 438 
 439 
 440 
Figure 4. Interaction of deiodinase chimeras with the WSB1 and TEB4 E3 ligases assessed with 441 
FRET 442 
(A) Experimental design. (B) FRET efficiency of chimeric deiodinases coexpressed with WSB1-C 443 
or C-TEB4 in HEK-293T cells. Data are expressed as a percentage of that of the fused CFP-YFP (C-444 
Y) tandem positive control while cotransfected monomeric CFP (C) and YFP (Y) were applied to 445 
detect non-specific background (mean ± SEM; n≥30 per group) ***: p<0.001; **: p<0.01 One-446 
way ANOVA vs. monomer followed by Tukey’s post-hoc test. (C) Photomicrography of individual 447 
HEK-293T cells demonstrating FRET between D1-D2 chimeric proteins and WSB1. (D) Same as 448 
(C) with TEB4. Each panel contains the following order of pictures: left-top: prebleach (pre) 449 
acceptor; right-top: postbleach (post) acceptor; left-bottom: prebleached donor; right-bottom: 450 
postbleached donor. The order of the fluorescent protein (C or Y) and the tagged protein in the 451 
name of the constructs reflects their position in the fusion protein. 452 
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